We report the case of a 60-year-old man who underwent open radical prostatectomy for prostate adenocarcinoma. He had no known cardiac disease or symptoms other than controlled hypertension and remote history of cocaine use. The patient was given sugammadex for reversal of neuromuscular blockade and, within 1 minute, developed severe, drug-resistant bradycardia followed by pulseless electrical activity arrest. Advanced cardiac life support was initiated and continued for 15 minutes before the return of spontaneous circulation. Subsequent cardiac workup showed no abnormalities. We believe the cause of arrest was sugammadex, considering the time of administration, the absence of cardiac disease, and stable operative course.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1213/XAA.0000000000000834 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comment on: "Cardiac arrest due to coronary vasospasm after sugammadex administration-a case report".
Korean J Anesthesiol
January 2025
Division of Neuroanaesthesiology, International Institute of Neurosciences, Aster Whitefield Hospital, Bengaluru, Karnataka, India.
We describe a case of profound bradyarrhythmia after sugammadex administration during ambulatory anesthesia. The patient was a 21-year-old man with autism spectrum disorder undergoing planned general anesthesia for dental treatment. After treatment completion, sugammadex was administered upon awakening, and sudden bradyarrhythmia appeared immediately.
View Article and Find Full Text PDFA real-world pharmacovigilance study of cardiac adverse events induced by sugammadex in the FDA adverse event reporting system.
Expert Opin Drug Saf
August 2024
Department of Structural Cardiology, Shandong Second Provincial General Hospital, Jinan, China.
Article Synopsis
- Sugammadex is a medication used to reverse muscle blockage during anesthesia, but recent reports indicate it may be associated with serious cardiac adverse events (CAEs).
- A study analyzed data from the FDA on CAEs related to sugammadex and found 19 incidents mainly involving cardiac arrhythmias and coronary artery disorders, with bradycardia and cardiac arrest being the most common issues.
- The findings suggest a potential connection between sugammadex and serious CAEs, emphasizing the importance of monitoring and assessing risks in patients with heart-related health concerns.
Asystolic cardiac arrest secondary to sugammadex administration in a young patient.
Anaesthesiol Intensive Ther
August 2024
Department of Anaesthesia, Queen Elizabeth Hospital, Lewisham & Greenwich NHS Trust, United Kingdom.
A pharmacovigilance study of FDA adverse events for sugammadex.
J Clin Anesth
October 2024
Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China. Electronic address:
Background: Sugammadex, a selective steroidal neuromuscular blocking agent reversal agent, is increasingly employed for the rapid restoration of neuromuscular function. This study aimed to conduct a comprehensive evaluation of sugammadex's safety profile.
Methods: Adverse events (AEs) related to sugammadex reported in the FDA Adverse Event Reporting System (FAERS) database from January 2009 to September 2023 were extracted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!